Nephrology Unit, "Mons. Dimiccoli" Hospital Barletta, Italy.
Nephrology Unit, "Mons. Dimiccoli" Hospital Barletta, Italy.
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2123-2132. doi: 10.1016/j.numecd.2020.09.013. Epub 2020 Sep 19.
This joint document of the Italian Society of Nephrology and the Italian Diabetes Society reviews the main indications to perform a renal biopsy in diabetic patients, according to the recommendations of a panel of experts based on all available scientific evidence.
Renal biopsy has a pivotal role in assessing the nature and severity of renal injury in patients with diabetic kidney disease (DKD). The procedure is mandatory in the presence of one of more of the following features: rapid onset or progression of albuminuria or sudden onset of nephrotic syndrome, rapid GFR decline with or without albuminuria, hematuria, active urine sediment, clinical and/or laboratory suspicion of other systemic diseases, and, in patients with type 1 diabetes, short diabetes duration and absence of retinopathy. Indeed, ~40% of diabetic individuals with kidney injury undergoing renal biopsy are affected by a non-diabetic renal disease (NDRD). Furthermore, the histological evaluation of patients with suspected classical diabetic nephropathy allows to define the extent of glomerular, tubulo-interstitial and vascular lesions, thus providing important prognostic (and potentially therapeutic) data. In the future, the indications for renal biopsy might be extended to the definition of the histological lesions underlying the "nonalbuminuric" DKD phenotypes, as well as to the evaluation of the response to treatment with the new anti-hyperglycemic drugs that provide cardiorenal protection.
In view of the heterogeneous clinical presentation and course of DKD and of the related heterogeneous histopathological patterns, a more extensive use of renal biopsy may be crucial to provide valuable information with important pathogenic, diagnostic, prognostic, and therapeutic implications.
意大利肾脏病学会和意大利糖尿病学会联合发布的这份文件,根据专家组基于所有现有科学证据提出的建议,回顾了在糖尿病患者中进行肾活检的主要适应证。
在糖尿病肾病(DKD)患者中,肾活检在评估肾脏损伤的性质和严重程度方面起着关键作用。在以下情况下,必须进行肾活检:蛋白尿迅速发生或进展,或肾病综合征突然发生,肾小球滤过率(GFR)快速下降,无论是否有蛋白尿,血尿,活动尿沉渣,临床和/或实验室怀疑存在其他全身性疾病,以及 1 型糖尿病患者,糖尿病病程短且无视网膜病变。实际上,约 40%的肾损伤糖尿病患者患有非糖尿病性肾脏疾病(NDRD)。此外,对疑似经典糖尿病肾病患者的组织学评估可确定肾小球、肾小管间质和血管病变的程度,从而提供重要的预后(和潜在治疗)数据。在未来,肾活检的适应证可能会扩展到定义“非白蛋白尿”DKD 表型的基础组织学病变,以及评估新型降糖药物治疗的反应,这些药物具有心脏和肾脏保护作用。
鉴于 DKD 的临床表现和病程以及相关的组织病理学表现存在异质性,更广泛地应用肾活检可能对提供具有重要发病机制、诊断、预后和治疗意义的有价值信息至关重要。